申请人:ASCENTAGE PHARMA (SUZHOU) CO., LTD.
公开号:US20220396587A1
公开(公告)日:2022-12-15
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R
1a
, R
1b
, L
1
, L
2
, L
3
, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.